RESUMO
OBJECTIVE: Ki67 is a prognostic and predictive marker in breast cancer (BC). However, manual scoring (MS) by visual assessment suffers from high inter-observer variability which limits its clinical use. Here, we developed a new digital image analysis (DIA) workflow, named KiQuant for automated scoring of Ki67 and investigated its equivalence with standard pathologist's assessment. METHODS: Sequential immunohistochemistry of Ki67 and cytokeratin, for precise tumor cell recognition, were performed in the same section of 5 tissue microarrays containing 329 tumor cores from different breast cancer subtypes. Slides were digitalized and subjected to DIA and MS for Ki67 assessment. The intraclass correlation coefficient (ICC) and Bland-Altman plot were used to evaluate inter-observer reproducibility. The Kaplan-Meier analysis was used to determine the prognostic potential. RESULTS: KiQuant showed an excellent correlation with MS (ICC:0.905,95%CI:0.878-0.926) with satisfactory inter-run (ICC:0.917,95%CI:0.884-0.942) and inter-antibody reproducibilities (ICC:0.886,95%CI:0.820-0.929). The distance between KiQuant and MS increased with the magnitude of Ki67 measurement and positively correlated with analyzed tumor area and breast cancer subtype. Agreement rates between KiQuant and MS within the clinically relevant 14% and 30% cut-off points ranged from 33% to 44% with modest interobserver reproducibility below the 20% cut-off (0.606, 95%CI:0.467-0.727). High Ki67 by KiQuant correlated with worse outcome in all BC and in the luminal subtype (Pâ¯=â¯0.028 and Pâ¯=â¯0.043, respectively). For MS, the association with survival was significant only in 1 out of 3 observers. CONCLUSIONS: KiQuant represents an easy and accurate methodology for Ki67 measurement providing a step toward utilizing Ki67 in the clinical setting.